ArticleJournal of the American Heart Association2026
Discontinuation of Heart Failure Pharmacotherapy in Older Adults With Frailty.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGuideline-directed medical therapy (GDMT) improves outcomes in heart failure irrespective of frailty status. Nevertheless, the magnitude of frailty-associated discontinuation of GDMT remains insufficiently studied. We aimed to quantify 12-month discontinuation rates of GDMT across frailty strata.
methodsThis retrospective cohort study used a nationwide insurer-based database. We identified patients aged ≥65 years who were hospitalized for heart failure between 2014 and 2022 and newly initiated on at least 1 GDMT at discharge, including angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor-neprilysin inhibitors, β-blockers, mineralocorticoid receptor antagonists, or SGLT2is (sodium-glucose cotransporter-2 inhibitors). Discontinuation was defined as a gap of 60 days without a prescription following the expected completion of the dispensed supply. The cumulative incidence of GDMT discontinuation within 12 months was estimated according to Hospital Frailty Risk Score, with death treated as a competing risk.
resultsWe analyzed 33 155 patients (mean age: 83.2 years, women: 53.0%). The initiating rates were as follows: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor-neprilysin inhibitors 48.3% (N=16 025), β-blockers 54.9% (N=18 197), mineralocorticoid receptor antagonists 44.1% (N=14 608), and SGLT2is 5.9% (N=1948). The Hospital Frailty Risk Score categories were as follows: low (33.2%), intermediate (47.1%), and severe (19.7%). Discontinuation rates increased with frailty severity: angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers/angiotensin receptor-neprilysin inhibitors 27.5%, 39.0%, 45.5% (for low, moderate, and high Hospital Frailty Risk Score, respectively,
conclusionsIn older adults with heart failure, approximately one-third discontinued GDMT within 12 months, and discontinuation appeared disproportionately common among those with frailty.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.